Beyond Air, Inc.: insider trades · United States · SEC (Form 4)

About Beyond Air, Inc.

Beyond Air, Inc. (NASDAQ: XAIR) is a U.S.-based medical device and biopharmaceutical company headquartered in Garden City, New York, United States. The company was originally known as AIT Therapeutics and adopted the Beyond Air name in 2019 as it sharpened its strategy around therapeutic nitric oxide (NO). For investors, the company sits in a specialized corner of the healthcare sector: respiratory care, hospital equipment, and nitric-oxide-based delivery technology. It is still relatively small in scale, but it is trying to build a differentiated commercial footprint around a clinically relevant platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1641631/000164117225015750/form10-k.htm?utm_source=openai)) Beyond Air’s core platform is LungFit, which uses its proprietary Ionizer™ technology to generate nitric oxide from ambient air, rather than relying on traditional cylinders or other cumbersome supply systems. That design is central to the investment case: the company is positioning LungFit as a simpler, more flexible, potentially cleaner way to deliver inhaled NO in hospital settings. Its flagship commercial product is LungFit PH, while other variants such as LungFit PRO and LungFit GO have been described by the company as investigational devices. Beyond Air also maintains a broader research and development effort around nitric oxide applications, with some adjacent business lines having been reorganized or moved into affiliated structures over time. ([beyondair.net](https://www.beyondair.net/?utm_source=openai)) Competitively, Beyond Air is seeking to challenge legacy nitric oxide delivery methods and compete with other respiratory technology providers by offering an on-demand, room-air-generated solution. The company’s message is straightforward: reduce logistical complexity, improve operational convenience for hospitals, and support a more scalable approach to NO therapy. That said, the business remains at an early commercial stage and faces the usual medtech execution risks, including hospital adoption rates, reimbursement dynamics, regulatory milestones, manufacturing readiness, and continued capital needs. In practical terms, the equity story still depends on proving that the technology can translate from clinical promise into repeatable commercial traction. ([beyondair.net](https://www.beyondair.net/?utm_source=openai)) Recent developments point to a company moving from development toward broader commercialization. In 2025, Beyond Air reported meaningful revenue growth, secured CE Mark for LungFit PH in Europe, obtained market authorization in Australia, and said international distribution agreements now provide access to more than 30 countries and over 2 billion lives. Management also highlighted a group purchasing agreement with Premier, Inc. and raised its fiscal 2026 revenue guidance. Taken together, these updates suggest that the commercial rollout is gaining momentum, although revenues remain modest and the company is still in the early innings of scaling its platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1641631/000149315225006892/ex99-1.htm?utm_source=openai))